Shots:

• The ODD is based on Omeros’ P-III program assessing OMS721 in patients with HSCT-TMA. Additionally- OMS721 is being evaluated in ongoing P-III program for IgA nephropathy- and aHUS respectively
• With the above designation OMS721 will serve in both prevention and treatment of HSCT-TMA in EU and the US. OMS721 also received ODD in IgA nephropathy- and aHUS- BT for IgA nephropathy & FTD for aHUS
• Omeros’ OMS721 is a mAb targeting MASP-2 while- holding WW rights for MASP-2 and all therapeutics targeting MASP-2 & developing small molecules for it. OMS721 also identified MASP-3 (for converting pro-factor D to factor D)

/ article | Ref: Omeros | Image: The Business Journals